You’ve heard the story: Trump’s MFN pricing and 15% tariffs on EU pharma, paired with China’s R&D surge, are finally killing Europe’s status as a pharma powerhouse. Drug launches in EU markets already dropped 35% in the 10 months after the MFN executive order, per GlobalData analysis. Companies are delaying entries to safeguard US pricing—Pfizer’s CEO put it bluntly: choose US prices or stop supplying France. Markets are rushing to price the collapse as an overnight event. Reality is harsher and older.
Europe’s global pharma R&D share has halved from roughly 50% in 1990 to 26-29% today, while the US holds 55%, according to ITIF and EFPIA-linked data. That slide started long before any Trump policy or Chinese acceleration. Europe still pours €55 billion into pharma R&D annually and generates over €366 billion in exports, yet its innovation footprint keeps shrinking. Money alone doesn’t fix a self-inflicted patchwork of 27 different regulatory, pricing, reimbursement, and clinical trial regimes. Fragmentation is the silent killer, and external pressure just exposes the wound.
Look at the growth rates: EU pharma R&D spending grew at a compounded 4.4% per year from 2010 to 2022, reaching €46.2 billion, per EFPIA figures. Over the same stretch the US managed 5.5% and China exploded at 20.7%. New active substances in Europe declined about 20% over the past decade while China’s pipeline surged—now accounting for nearly one-third of global molecules in development, up from 4% a decade ago. Consensus wants to credit recent Chinese momentum or Trump shocks for the shift. The numbers say Europe lost the race on speed and scale years ago through its own fragmented capital markets and slow single-market adoption.
Even €55 billion a year in R&D spending can’t overcome the reality that launching in Europe means navigating uneven reimbursement and delayed access that protects neither patients nor future innovation. US hubs in Boston and the Bay Area consolidate trials and capital; Europe’s setup scatters them. The deadpan fact bomb: Europe invests €55 billion yearly in pharma R&D and racks up €366 billion in exports, yet its share of global innovation has halved over 35 years—proving cash without cohesion buys decline, not dominance.
This isn’t sudden vulnerability. It’s structural erosion that tariffs and China’s boom merely highlight. Companies have lamented the fragmentation for years: uneven policies across member states, parallel trade draining resources, and slower trial starts compared to consolidated US or accelerating Chinese environments. The result? Europe now captures far less of the upside from its own spending. US firms originate nearly half of recent global new therapies; Europe is down to around a quarter in recent periods, a reversal from its 1990s dominance.
Tariffs and China expose rather than cause the weakness. Europe’s self-made regulatory maze has already ceded ground in advanced therapies, where US and Chinese clinical trial activity dwarfs Europe’s. If you own European pharma names or bet on regional stability, ask what changes when the next wave of innovation simply routes around the continent. The market’s crowded consensus on “external shocks killing Europe” misses the longer, internal story—the one written in decades of lagging growth rates and shrinking shares.